Unlocking the combined potential of SGLT2i and GLP-1 RA mechanisms for organ protection

Chair: Hiddo L. Heerspink (NLD)

13:00 – 13:10Welcome and introductionsHiddo L. Heerspink (NLD)
13:10 – 13:25SGLT2is and GLP-1 RAs: Defined mechanisms, combined impact on cellular healthMichael Roden (DEU)
13:25 – 13:40Turning the cogs: Clinical evidence of SGLT2is and
GLP-1 RAs for kidney protection		Hiddo L. Heerspink (NLD)
13:40 – 13:55Unlocking the potential of SGLT2is and GLP-1 RAs for CV protectionBiykem Bozkurt (USA)
13:55 – 14:25Looking to the future: The combined potential for SGLT2is and GLP-1 RAs to improve CV, renal, and metabolic healthAll faculty
14:25 – 14:30Summary and closeHiddo L. Heerspink (NLD)
AstraZeneca logo
  • Monday, 15 September 2025
  • 13:00 - 14:30 CEST
  • Warsaw Hall